For a hedged play on Ligand Pharmaceuticals (LGND), MarketIntelligenceCenter.com’s option-trade picking algorithms recommend the Jun 15, 2018 $155 covered call for a net debit in the $149.08 area. That is also the break-even stock …
While the PR spin employed by LGND's management is ingenious and certainly has levitated the stock price, investors appear to be buying a bill of goods at current share price levels. Our conclusion is that LGND is significantly overvalued …
That’s why I found 10 stocks to buy instead of bitcoin ... return of sub 17%, CAT stock is up almost 31% in the past six months. The good times are back for this construction giant. Ligand Pharmaceuticals Inc (NASDAQ:LGND) is a new …
Mr. Charles S. Berkman J.D. is Vice President, General Counsel, Secretary of the Company. He joined the Company in November 2001 and previously served as Associate General Counsel and Chief Patent Counsel for the Company (and …
Ligand Pharmaceuticals Inc. LGND is scheduled to report third-quarter 2017 results ... Quote Ligand’s shares have outperformed the industry so far this year. The stock has rallied 44.1% compared with the industry’s 3.9% increase. …
The stock is currently near all-time highs, offers long term value investment proposition. By S. Mitra, MBA (ISB) Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has a unique business model that differs markedly from traditional biotech …
Ligand Pharmaceuticals Inc. LGND reported third-quarter 2017 adjusted earnings of ... Ligand’s shares have outperformed the industry year to date. The stock has soared 42.5% compared with the industry’s 2.7% increase. View photos Total …